PBAC's latest decision on Durvalumab and tremelimumab: Recommended with restriction (2025). Considered for First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer (BCLC) Stage B or Stage C hepatocellular carcinoma (HCC).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients with advanced (unresectable) BCLC Stage B or Stage C HCC, WHO performance status 0 or 1, not suitable for transarterial chemoembolisation, with Child Pugh class A, untreated with systemic therapy or intolerant to atezolizumab or VEGF inhibitor TKI.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Pivotal trial size
393 patients
Key trials
HIMALAYA, IMBRAVE150
Comparator
atezolizumab plus bevacizumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated by design.